Search research articles
Contact Us
Filters
Showing results (1-10 of 46) with videos related to
Page
of 5
Sort By:
Annals of Internal Medicine
|
April 7, 2017
Should We Screen for Type 2 Diabetes?
David M Rind
JAMA
|
May 1, 2024
The FDA and Gene Therapy for Duchenne Muscular Dystrophy
David M Rind
The New England Journal of Medicine
|
November 26, 2010
Retinopathy progression in type 2 diabetes
David M Rind
The New England Journal of Medicine
|
August 19, 2007
Antiretroviral drugs and the risk of myocardial infarction
Todd M Pollack, David M Rind
Annals of Internal Medicine
|
October 5, 2016
Should We Screen for Type 2 Diabetes?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center
Gerald W Smetana, Martin J Abrahamson, David M Rind
Applied Health Economics and Health Policy
|
December 2, 2024
Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA
Jyotirmoy Sarker, Jeffrey A Tice, David M Rind, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 28, 2024
How Do the Institute for Clinical and Economic Review's Assessments of Comparative Effectiveness Compare With the German Federal Joint Committee's Assessments of Added Benefit? A Qualitative Study
Michael J DiStefano, Steven D Pearson, David M Rind, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 22, 2022
The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19
Melanie D Whittington, Steven D Pearson, David M Rind, et al.
International Journal of Medical Informatics
|
June 21, 2008
Association of a clinical knowledge support system with improved patient safety, reduced complications and shorter length of stay among Medicare beneficiaries in acute care hospitals in the United States
Peter A Bonis, Gary T Pickens, David M Rind, et al.
Schizophrenia Research
|
September 30, 2024
A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia
Abigail C Wright, Avery McKenna, Jeffrey A Tice, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 46) with videos related to
Sort By:
Page
of 5
Annals of Internal Medicine
|
April 7, 2017
Should We Screen for Type 2 Diabetes?
David M Rind
JAMA
|
May 1, 2024
The FDA and Gene Therapy for Duchenne Muscular Dystrophy
David M Rind
The New England Journal of Medicine
|
November 26, 2010
Retinopathy progression in type 2 diabetes
David M Rind
The New England Journal of Medicine
|
August 19, 2007
Antiretroviral drugs and the risk of myocardial infarction
Todd M Pollack, David M Rind
Annals of Internal Medicine
|
October 5, 2016
Should We Screen for Type 2 Diabetes?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center
Gerald W Smetana, Martin J Abrahamson, David M Rind
Applied Health Economics and Health Policy
|
December 2, 2024
Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA
Jyotirmoy Sarker, Jeffrey A Tice, David M Rind, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 28, 2024
How Do the Institute for Clinical and Economic Review's Assessments of Comparative Effectiveness Compare With the German Federal Joint Committee's Assessments of Added Benefit? A Qualitative Study
Michael J DiStefano, Steven D Pearson, David M Rind, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 22, 2022
The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19
Melanie D Whittington, Steven D Pearson, David M Rind, et al.
International Journal of Medical Informatics
|
June 21, 2008
Association of a clinical knowledge support system with improved patient safety, reduced complications and shorter length of stay among Medicare beneficiaries in acute care hospitals in the United States
Peter A Bonis, Gary T Pickens, David M Rind, et al.
Schizophrenia Research
|
September 30, 2024
A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia
Abigail C Wright, Avery McKenna, Jeffrey A Tice, et al.
Page
of 5